These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 31646557)
1. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway. Liu FH; Cui YP; He YK; Shu RH Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557 [TBL] [Abstract][Full Text] [Related]
2. LncRNA HOTAIRM1 inhibits the progression of hepatocellular carcinoma by inhibiting the Wnt signaling pathway. Zhang Y; Mi L; Xuan Y; Gao C; Wang YH; Ming HX; Liu J Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4861-4868. PubMed ID: 30070317 [TBL] [Abstract][Full Text] [Related]
3. miRNA-217 inhibits proliferation of hepatocellular carcinoma cells by regulating KLF5. Gao W; Lu YX; Wang F; Sun J; Bian JX; Wu HY Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7874-7883. PubMed ID: 31599412 [TBL] [Abstract][Full Text] [Related]
4. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103. Ma CX; Gao WC; Tian L Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297 [TBL] [Abstract][Full Text] [Related]
5. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway. Wu JZ; Jiang N; Lin JM; Liu X Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415 [TBL] [Abstract][Full Text] [Related]
6. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT. Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354 [TBL] [Abstract][Full Text] [Related]
7. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway. Fang D; Wang MR; Guan JL; Han YY; Sheng JQ; Tian DA; Li PY Exp Cell Res; 2021 Sep; 406(2):112727. PubMed ID: 34370992 [TBL] [Abstract][Full Text] [Related]
8. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway. Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743 [TBL] [Abstract][Full Text] [Related]
9. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway. Liu Y; Ma J; Lu S; He P; Dong W Chin Med J (Engl); 2023 Sep; 136(18):2229-2242. PubMed ID: 37439386 [TBL] [Abstract][Full Text] [Related]
10. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Lei T; Zhu X; Zhu K; Jia F; Li S Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558 [TBL] [Abstract][Full Text] [Related]
11. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway. Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806 [TBL] [Abstract][Full Text] [Related]
12. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/β-catenin signaling pathway activation in hepatocellular carcinoma cells. Fan Q; Yang L; Zhang X; Ma Y; Li Y; Dong L; Zong Z; Hua X; Su D; Li H; Liu J J Exp Clin Cancer Res; 2018 Jan; 37(1):9. PubMed ID: 29351758 [TBL] [Abstract][Full Text] [Related]
13. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling. Li Z; Xue TQ; Yang C; Wang YL; Zhu XL; Ni CF J Cell Biochem; 2018 Dec; 119(12):10327-10337. PubMed ID: 30129142 [TBL] [Abstract][Full Text] [Related]
14. MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT. Fang J; Chen YL; Yao HB; Peng SS; Yang P; Ding ZY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2335-2346. PubMed ID: 32196585 [TBL] [Abstract][Full Text] [Related]
15. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin. Li H; Yuan R; Wang H; Li C; Wei J J BUON; 2020; 25(2):972-980. PubMed ID: 32521894 [TBL] [Abstract][Full Text] [Related]
16. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway. Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392 [TBL] [Abstract][Full Text] [Related]
17. LRP16 prevents hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling. Shao L; Jing W; Wang L; Pan F; Wu L; Zhang L; Yang P; Hu M; Fan K J Mol Med (Berl); 2018 Jun; 96(6):547-558. PubMed ID: 29748698 [TBL] [Abstract][Full Text] [Related]
18. ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK-3β/Wnt/β-catenin signalling. Li W; Xue H; Li Y; Li P; Ma F; Liu M; Kong S Clin Exp Pharmacol Physiol; 2019 Sep; 46(9):845-853. PubMed ID: 31168819 [TBL] [Abstract][Full Text] [Related]
19. Nek2B accelerates the progression of hepatocellular carcinoma through regulating SFRP1 to activate the Wnt/β-catenin pathway. Li L; Ye Y; Ran Y; Zhou Y; Dang Z; Su X; Hu S J BUON; 2021; 26(3):861-867. PubMed ID: 34268946 [TBL] [Abstract][Full Text] [Related]